nintedanib and Psoriasis

Psoriasis is a common chronic skin disorder characterized by keratinocyte hyperproliferation with altered differentiation accompanied by increased inflammation and angiogenesis. Nintedanib is a tyrosine kinase inhibitor that has anti-inflammatory, anti-angiogenesis, and anti-fibrotic effects. In this study, we explored the potential effects and mechanisms of nintedanib on psoriasis in vivo and in vitro. In vivo experiments showed that nintedanib effectively alleviated imiquimod-induced psoriasis-like skin lesions and reduced psoriasis severity index scores. For the mechanism research, we mainly focused on the abnormal phenotype of keratinocyte in the pathogenesis of psoriasis. We used HaCaT cells in the in vitro experiments and the result revealed that nintedanib restored keratinocyte homeostasis by downregulated the expression of proinflammatory factors, inhibited hyperproliferation, promoted apoptosis, maintained normal differentiation via regulating the NF-κB pathway. In addition, nintedanib regulated angiogenesis by inhibiting VEGFR2 activity. In summary, our study indicated that nintedanib is a promising candidate medication for psoriatic treatment.

Topics: Animals; Apoptosis; Cell Proliferation; Cytokines; HaCaT Cells; Humans; Imiquimod; Indoles; Inflammation; Keratinocytes; Male; Mice; Mice, Inbred BALB C; Neovascularization, Physiologic; NF-kappa B; Psoriasis; Signal Transduction; Skin; Vascular Endothelial Growth Factor Receptor-2

Topics: Aged; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Protein Kinase Inhibitors; Psoriasis; Remission Induction; Severity of Illness Index; Treatment Outcome